InveniAI Launches Suite of Products Powered by AlphaMeld , an Artificial Intelligence Platform, to Enable Robust Decision Making for Multiple Stakeholders in the Life Sciences - Inveniai

GUILFORD, Conn., Sept. 17, 2019 -- InveniAI Corporation, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries, today announced the expansion of its flagship AI- and ML-driven innovation monitoring platform, AlphaMeld . This expansion will provide a suite of products to facilitate the democratization of data analysis across the life sciences value chain and tap into InveniAI's extensive domain expertise and curated data sets that have been aligned with industry specific algorithms. CIMeld, an AlphaMeld powered product, will be launched at the upcoming PharmaCI USA 2019 Conference and Exhibition set for September 18-19, where competitive intelligence executives in pharma, biotech and medical devices meet at one of the largest CI assemblies in the world. CIMeld is a unique product that takes advantage of the digital data deluge and leverages AI-powered technology to triangulate signals from multiple sources to generate insights and identify opportunities and threats across diseases, companies, drug portfolios, and early innovation. The AlphaMeld suite of products is accessible via a secure, customized, cloud-based interface with the option to personalize the definition of success and failure that lends a unique competitive advantage to its users.